肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
Cancer Research and Clinic
2015年
9期
620-623
,共4页
肝肿瘤%射频消融%外科手术
肝腫瘤%射頻消融%外科手術
간종류%사빈소융%외과수술
Liver neoplasms%Radiofrequency ablation%Surgical procedures,operative
目的:观察三维图像重建及超声引导下经皮射频消融与手术切除治疗小肝癌的临床疗效。方法回顾性分析山西省肿瘤医院2009年1月至2012年3月收治的94例原发性小肝癌患者的临床资料,其中接受超声引导下经皮射频消融治疗45例(射频组),手术切除治疗49例(手术组),两组患者治疗前均进行CT三维图像重建。对比两组患者的肿瘤复发率、总生存率及并发症发生率等。结果射频组患者治疗后1、2、3年的总生存率分别为95.56%(43/45)、86.67%(39/45)、60.00%(27/45),与手术组的93.88%(46/49)、79.60%(39/49)、59.20%(29/49)比较,差异均无统计学意义(均P>0.05)。两组患者1、2、3年肿瘤复发率比较,差异均无统计学意义(均P>0.05)。射频组患者术后疼痛发生率为13.33%(6/45),手术组为100.00%(49/49),差异有统计学意义(χ2=60.416, P<0.05)。两组其余并发症发生率差异亦有统计学意义(P<0.05)。截至2015年3月,射频组患者未发现针道种植转移。结论对直径小于3 cm的原发性小肝癌,在CT三维图像重建及超声引导下行射频消融治疗具有疗效好、创伤小、并发症少、费用低、可多次重复的优势,总体疗效与手术切除相近,可作为小肝癌的首选治疗手段。
目的:觀察三維圖像重建及超聲引導下經皮射頻消融與手術切除治療小肝癌的臨床療效。方法迴顧性分析山西省腫瘤醫院2009年1月至2012年3月收治的94例原髮性小肝癌患者的臨床資料,其中接受超聲引導下經皮射頻消融治療45例(射頻組),手術切除治療49例(手術組),兩組患者治療前均進行CT三維圖像重建。對比兩組患者的腫瘤複髮率、總生存率及併髮癥髮生率等。結果射頻組患者治療後1、2、3年的總生存率分彆為95.56%(43/45)、86.67%(39/45)、60.00%(27/45),與手術組的93.88%(46/49)、79.60%(39/49)、59.20%(29/49)比較,差異均無統計學意義(均P>0.05)。兩組患者1、2、3年腫瘤複髮率比較,差異均無統計學意義(均P>0.05)。射頻組患者術後疼痛髮生率為13.33%(6/45),手術組為100.00%(49/49),差異有統計學意義(χ2=60.416, P<0.05)。兩組其餘併髮癥髮生率差異亦有統計學意義(P<0.05)。截至2015年3月,射頻組患者未髮現針道種植轉移。結論對直徑小于3 cm的原髮性小肝癌,在CT三維圖像重建及超聲引導下行射頻消融治療具有療效好、創傷小、併髮癥少、費用低、可多次重複的優勢,總體療效與手術切除相近,可作為小肝癌的首選治療手段。
목적:관찰삼유도상중건급초성인도하경피사빈소융여수술절제치료소간암적림상료효。방법회고성분석산서성종류의원2009년1월지2012년3월수치적94례원발성소간암환자적림상자료,기중접수초성인도하경피사빈소융치료45례(사빈조),수술절제치료49례(수술조),량조환자치료전균진행CT삼유도상중건。대비량조환자적종류복발솔、총생존솔급병발증발생솔등。결과사빈조환자치료후1、2、3년적총생존솔분별위95.56%(43/45)、86.67%(39/45)、60.00%(27/45),여수술조적93.88%(46/49)、79.60%(39/49)、59.20%(29/49)비교,차이균무통계학의의(균P>0.05)。량조환자1、2、3년종류복발솔비교,차이균무통계학의의(균P>0.05)。사빈조환자술후동통발생솔위13.33%(6/45),수술조위100.00%(49/49),차이유통계학의의(χ2=60.416, P<0.05)。량조기여병발증발생솔차이역유통계학의의(P<0.05)。절지2015년3월,사빈조환자미발현침도충식전이。결론대직경소우3 cm적원발성소간암,재CT삼유도상중건급초성인도하행사빈소융치료구유료효호、창상소、병발증소、비용저、가다차중복적우세,총체료효여수술절제상근,가작위소간암적수선치료수단。
Objective To comparison between radiofrequency ablation introduced by tri-dimension reconstruction and ultrasound and operation for the treatment of small hepatocellular carcinoma. Methods 94 patients with small hepatocellular carcinoma from Jan 2009 to Mar 25 in Shanxi Cancer Hospital were analyzed. 45 patients were both given CT examination to rebuild tri-dimension and radiofrequency ablation treatment. 49 patients were given excision. Both groups were given CT examination to rebuild tri-dimension before the treatment. The differences in recurrence rate, overall survival and complication ratio between the two groups were compared. Results After 1, 2 and 3 years radiofrequency ablation treatment, the survival rate in radiofrequency ablation group were 95.56 % (43/45), 86.67 % (39/45), 60.00 % (27/45) respectively, comparing with 93.88%(46/49), 79.60%(39/49), 59.20%(29/49) in operation group. The difference was not statistically significant (P>0.05). There was no statistical significance in 1-year, 2-year and 3-year recurrence rates between the two groups (P> 0.05). There were statistical significances in incidence of post-treatment pains [13.33%(6/45) vs 100.00%(49/49),χ2=60.416, P<0.05] and complication (P<0.05) between the two groups. By Mar 25th, 2015, there was no needle tract implantation in the patients with radiofrequency ablation treatment. Conclusions For the small hepatocellular carcinoma with less than 3cm in diameter, introduced by CT tri-dimension image reconstruction and ultrasound, the radiofrequency ablation treatment excels in effect with fewer damages, infective complications, lower cost and can be applied many times. The overall effect is close to surgical removal, and therefore it can be used as the first line therapy for small hepatocellular carcinoma.